Science

Jun 16, 2025, 16:01

Myeloma Paper of the Day, June 16th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: EMMY study of patients retreated with anti-CD38 shows median PFS of 5.1 months (23.6 in patients sensitive to anti-CD38 vs. 4.6 if non-sensitive; median OS 17.3 months for all patients (14.8 mos in non-sensitive vs. NR in sensitive).”

Title: Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study

Authors: Alexis Talbot, Cyrille Hulin, Aurore Perrot, Margaret Macro, Karim Belhadj Merzoug, Mohamed Mohty, Arthur Bobin, Lionel Karlin, Salomon Manier, Laure Vincent, Abderrazak El Yamani, Wajed Abarah, Regis Kaphan, Thomas Chalopin, Daniel Ré, Adrienne de Labarthe, Olivier Fitoussi, Chanaz Lounis, Ronan Garlantezec, Olivier Decaux

You can read the Full Article in Clinical Lymphoma, Myeloma and Leukemia.

More posts featuring Robert Orlowski.

Abderrazak El Yamani Adrienne de Labarthe Alexis Talbot Arthur Bobin Aurore Perrot cancer Chanaz Lounis Cyrille Hulin Daniel Ré Emmy Cohort Karim Belhadj-Merzoug Laure Vincent Lionel Karlin Margaret Macro Mohamed Mohty multiple myeloma Myeloma Myeloma Paper of the Day Olivier Decaux Olivier Fitoussi OncoDaily Oncology Regis Kaphan Robert Orlowski Ronan Garlantézec Salomon Manier Thomas Chalopin Wajed Abarah

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology